NL-OMON55742已完成不适用
Pharmacokinetic boosting of osimertinib in patients with non-small cell lung cancer. - OSIBOOST
Medisch Universitair Ziekenhuis Maastricht0 个研究点目标入组 29 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 29
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •- Patients with EGFR-mutated NSCLC receiving standard treatment with
- •osimertinib for at least 2 months (steady-state) without any signs of disease
- •progression, or during treatment beyong progression, if treatment for another
- •couple of months is expected. After anticipated EMA approval of osimertinib
- •adjuvant therapy, patients on adjuvant osimertinib treatment may also
- •participate on the following conditions: if they are receiving standard
- •treatment with osimertinib for at least 2 months (steady-state), and if
- •treatment will be continued for a longer period than necessary for
- •participation in the OSIBOOST-trial.
- •- Patients with osimertinib plasma trough concentration below 195 ng/ml.
- •- Age * 18 years
- •- WHO performance status * 2.
- •- Able and willing to give written informed consent.
- •- Able and willing to undergo blood sampling for pharmacokinetic analysis.
排除标准
- •- Any concurrent medication that is known to strongly inhibit or induce CYP3A4.
- •- Refusing to retain from consuming CYP3A4-influencing products, such as St
- •John's wort or grapefruitjuice).
- •- Pregnancy of breast feeding.
研究者
相似试验
进行中（未招募）
1 期
Study to osimertinib treatment in patients with lung cancer.on-small cell lung carcinomaEUCTR2018-004290-28-NL20
进行中（未招募）
2 期
A Phase 2 Study of Osimertinib in combination with Platinum-pemetrexed in patients with EGFR-mutated Advanced non-small cell Lung cancer.on-squamous non-small cell lung cancerJPRN-jRCTs031180226Kobayashi Kunihiko66
已完成
不适用
Observational study of osimertinib for patients with locally advanced/metastatic non-small cell lung cancer who are harboring T790M mutation detected by liquid biopsy and whose disease has progressed with previous EGFR-TKI therapy(WJOG8815LFS)EGFR mutation positive advanced or metastatic NSCLCJPRN-UMIN000034682West Japan Oncology Group33
已完成
不适用
A phase II study of osimertinib in patients with poor performance status and EGFR mutation T790M-positive non-small-cell lung cancerPatients with poor performance status and EGFR mutation T790M-positive non-small-cell lung cancerJPRN-UMIN000027655Division of Thoracic Oncology, Shizuoka cancer center18
招募中
不适用
Phase II study of osimertinib in patients with non-small cell lung cancer who acquired resistance to afatinibon-small cell lung cancerJPRN-UMIN000028166Asahikawa Medical University Hospital50